Neoadjuvant Systemic Therapy in Breast Cancer

Семиглазов, Владимир

doi:10.5772/23288

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2021

Publication Types

Select...

Article1

Other1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 49 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous clinical studies have indicated that breast cancer patients with HER2 overexpression typically demonstrate a poor prognosis and a high degree of malignancy in tumorous biological behavior. 9 In recent years, the increasing clinical application of trastuzumab has a significantly improved disease-free survival, overall survival, and PRC rate of patients. 10 This improvement in the outcomes has come at the cost of increased cardiotoxicity.…”

mentioning

confidence: 99%

Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types

Mao

Wang

2021

American Journal of Therapeutics

View full text Add to dashboard Cite

mentioning

confidence: 99%

Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types

Mao

Wang

2021

American Journal of Therapeutics

View full text Add to dashboard Cite

Clinical Insights: Neoadjuvant Therapy in Breast Cancer

Campone¹,

Frenel²

2014

View full text Add to dashboard Cite

Although the author and publisher have made every effort to ensure accuracy of published drug doses and other medical information, they take no responsibility for errors, omissions, or for any outcomes related to the book contents and take no responsibility for the use of any products described within the book. No claims or endorsements are made for any marketed drug or putative therapeutic agent under clinical investigation. Any product mentioned in the book should be used in accordance with the prescribing information prepared by the manufacturers, and ultimate responsibility rests with the prescribing physician.

show abstract

Neoadjuvant Systemic Therapy in Breast Cancer

Cited by 2 publications

References 49 publications

Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types

Neoadjuvant Chemotherapy in Synchronous Bilateral Breast Cancer With Different HER2 Types

Clinical Insights: Neoadjuvant Therapy in Breast Cancer

Contact Info

Product

Resources

About